We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmon... Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology. Show more
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: BofA Securities Health Care Conference on Tuesday, May 14 at...
โ Additional Data in Pregnant Adults Who Are Virologically Suppressed Reinforce Safety and Tolerability Profile of Biktarvy in Broad Range of People With HIV โ โ Perinatal Guidelines Recognize...
Exxon Mobil (NYSE:XOM) – Shares of Exxon Mobil are down 1.7% in pre-market trading after reporting first-quarter earnings below forecasts, affected by pressure on refining margins and...
Product Sales Excluding Veklury Increased 6% Year-Over-Year to $6.1 billion Biktarvy Sales Increased 10% Year-Over-Year to $2.9 billion Oncology Sales Increased 18% Year-Over-Year to $789 million...
U.S. index futures fell in pre-market trading on Thursday, particularly technology stocks, which saw a significant depreciation after Meta Platforms (NASDAQ:META) announced disheartening...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2024 financial results and guidance will be released on Thursday, April 25, 2024, after the market closes. At 4:30 p.m...
โ Efficacy and Safety Profile of Once-Daily Vemlidy Demonstrated in Children Six Years of Age (Weighing at Least 25kg) and Older โ Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the...
โ Gilead Granted Exclusive License to Xilioโs Tumor-Activated IL-12 Program, Including XTX301, a Clinical-Stage IL-12 Molecule with Potential to Treat a Broad Range of Cancers โ Gilead Sciences...
Acquisition Reinforces Gileadโs Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously...
The Center for Disease Analysis Foundation (CDA Foundation) is thrilled to announce the first-round recipients of the CDAF-Relink grant to connect Hepatitis B and C infected individuals in the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.71 | -1.08396946565 | 65.5 | 66.91 | 64.33 | 8091128 | 65.48402419 | CS |
4 | -4.9 | -7.0311378964 | 69.69 | 70.0098 | 64.33 | 7297316 | 66.8814779 | CS |
12 | -9.01 | -12.2086720867 | 73.8 | 76.21 | 64.33 | 7263484 | 70.98168636 | CS |
26 | -17.21 | -20.987804878 | 82 | 87.865 | 64.33 | 7198578 | 75.43195557 | CS |
52 | -16.14 | -19.9431607562 | 80.93 | 87.865 | 64.33 | 6336935 | 76.29491978 | CS |
156 | 0.8694 | 1.36012490496 | 63.9206 | 89.74 | 57.165 | 7115728 | 71.62205161 | CS |
260 | -1.18 | -1.78869182962 | 65.97 | 89.74 | 56.56 | 8285775 | 70.32934779 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions